报价延迟最少15分钟:2025/11/07 13:13 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.035 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.45/-0.09
|
|
企业价值
1.57B
|
| 资产负债 |
|
每股账面净值
2.59
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
796.97M
|
|
每股收益
2.45
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/07 13:13 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000employees and 18 production sites mainly in Europe and the United States. |
